[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100402145":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":47,"centralContacts":65,"locations":71,"responsibleParty":308,"collaborators":47,"id":310,"slug":311,"hasResults":312,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":312,"sex":318,"minAge":319,"maxAge":47,"enrollmentInfo":320,"targetDuration":47,"studyType":323,"phases":324,"briefSummary":326,"conditions":327,"keywords":332,"overallStatus":74,"whyStopped":47,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":342},{"fullName":5,"class":6},"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","INDUSTRY",[8,15,20,25,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Azenosertib + carboplatin","EXPERIMENTAL","Azenosertib in combination with carboplatin",[13,14],"Drug: Azenosertib","Drug: Carboplatin",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1: Azenosertib + PLD","Azenosertib in combination with pegylated liposomal doxorubicin (PLD)",[13,19],"Drug: Pegylated liposomal doxorubicin",{"label":21,"type":10,"description":22,"interventionNames":23},"Part 1: Azenosertib + paclitaxel","Azenosertib in combination with paclitaxel",[13,24],"Drug: Paclitaxel",{"label":26,"type":10,"description":27,"interventionNames":28},"Part 1: Azenosertib + gemcitabine","Azenosertib in combination with gemcitabine",[13,29],"Drug: Gemcitabine",{"label":31,"type":10,"description":32,"interventionNames":33},"Part 2: Azenosertib + bevacizumab","Azenosertib in combination with bevacizumab",[13,34],"Biological: Bevacizumab",[36,43,48,52,56,60],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","Azenosertib","Investigational drug",[16,9,26,21,31],[42],"ZN-c3",{"type":37,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"Carboplatin","Carboplatin is an approved drug",[9],null,{"type":37,"name":49,"description":50,"armGroupLabels":51,"otherNames":47},"Pegylated liposomal doxorubicin","Pegylated liposomal doxorubicin (PLD) is an approved drug",[16],{"type":37,"name":53,"description":54,"armGroupLabels":55,"otherNames":47},"Paclitaxel","Paclitaxel is an approved drug",[21],{"type":37,"name":57,"description":58,"armGroupLabels":59,"otherNames":47},"Gemcitabine","Gemcitabine is an approved drug",[26],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":47},"BIOLOGICAL","Bevacizumab","Bevacizumab is an approved drug",[31],[66],{"name":67,"role":68,"phone":69,"phoneExt":47,"email":70},"K-Group, Beta, Inc., a subsidiary of Zentalis Pharmaceuticals","CONTACT","8582634333","medicalaffairs@zentalis.com",[72,86,96,106,115,125,135,146,156,168,177,187,197,203,213,224,233,242,253,262,273,284,293,302],{"facility":73,"status":74,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":47},"Site 0264","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":81,"coordinates":82},"Point",[83,84],-104.83192,39.72943,{"lat":84,"lon":83},{"facility":87,"status":74,"city":88,"state":89,"zip":90,"country":78,"countryCode":79,"cosmosGeoPoint":91,"geoPoint":95,"contacts":47},"Site 0104","Boston","Massachusetts","02215",{"type":81,"coordinates":92},[93,94],-71.05977,42.35843,{"lat":94,"lon":93},{"facility":97,"status":74,"city":98,"state":99,"zip":100,"country":78,"countryCode":79,"cosmosGeoPoint":101,"geoPoint":105,"contacts":47},"Site 0111","St Louis","Missouri","53110",{"type":81,"coordinates":102},[103,104],-90.19789,38.62727,{"lat":104,"lon":103},{"facility":107,"status":74,"city":108,"state":108,"zip":109,"country":78,"countryCode":79,"cosmosGeoPoint":110,"geoPoint":114,"contacts":47},"Site 0173","New York","10029",{"type":81,"coordinates":111},[112,113],-74.00597,40.71427,{"lat":113,"lon":112},{"facility":116,"status":74,"city":117,"state":118,"zip":119,"country":78,"countryCode":79,"cosmosGeoPoint":120,"geoPoint":124,"contacts":47},"Site 0259","Durham","North Carolina","27710",{"type":81,"coordinates":121},[122,123],-78.89862,35.99403,{"lat":123,"lon":122},{"facility":126,"status":74,"city":127,"state":128,"zip":129,"country":78,"countryCode":79,"cosmosGeoPoint":130,"geoPoint":134,"contacts":47},"Site 0191","Providence","Rhode Island","02905",{"type":81,"coordinates":131},[132,133],-71.41283,41.82399,{"lat":133,"lon":132},{"facility":136,"status":137,"city":138,"state":139,"zip":140,"country":78,"countryCode":79,"cosmosGeoPoint":141,"geoPoint":145,"contacts":47},"Site 0196","COMPLETED","Nashville","Tennessee","37203",{"type":81,"coordinates":142},[143,144],-86.78444,36.16589,{"lat":144,"lon":143},{"facility":147,"status":74,"city":148,"state":149,"zip":150,"country":78,"countryCode":79,"cosmosGeoPoint":151,"geoPoint":155,"contacts":47},"Site 0103","Houston","Texas","77030",{"type":81,"coordinates":152},[153,154],-95.36327,29.76328,{"lat":154,"lon":153},{"facility":157,"status":137,"city":158,"state":159,"zip":160,"country":161,"countryCode":162,"cosmosGeoPoint":163,"geoPoint":167,"contacts":47},"Site 2707","South Brisbane","Queensland","4101","Australia","AU",{"type":81,"coordinates":164},[165,166],153.02049,-27.48034,{"lat":166,"lon":165},{"facility":169,"status":137,"city":170,"state":159,"zip":171,"country":161,"countryCode":162,"cosmosGeoPoint":172,"geoPoint":176,"contacts":47},"Site 2708","Sunshine Coast","4556",{"type":81,"coordinates":173},[174,175],153.07955,-26.65682,{"lat":175,"lon":174},{"facility":178,"status":137,"city":179,"state":180,"zip":181,"country":161,"countryCode":162,"cosmosGeoPoint":182,"geoPoint":186,"contacts":47},"Site 2709","Adelaide","South Australia","5000",{"type":81,"coordinates":183},[184,185],138.59863,-34.92866,{"lat":185,"lon":184},{"facility":188,"status":74,"city":189,"state":190,"zip":191,"country":161,"countryCode":162,"cosmosGeoPoint":192,"geoPoint":196,"contacts":47},"Site 2716","Melbourne","Victoria","3121",{"type":81,"coordinates":193},[194,195],144.96332,-37.814,{"lat":195,"lon":194},{"facility":198,"status":74,"city":189,"state":190,"zip":199,"country":161,"countryCode":162,"cosmosGeoPoint":200,"geoPoint":202,"contacts":47},"Site 2706","3144",{"type":81,"coordinates":201},[194,195],{"lat":195,"lon":194},{"facility":204,"status":74,"city":205,"state":206,"zip":207,"country":161,"countryCode":162,"cosmosGeoPoint":208,"geoPoint":212,"contacts":47},"Site 2705","Nedlands","Western Australia","6009",{"type":81,"coordinates":209},[210,211],115.8073,-31.98184,{"lat":211,"lon":210},{"facility":214,"status":137,"city":215,"state":47,"zip":216,"country":217,"countryCode":218,"cosmosGeoPoint":219,"geoPoint":223,"contacts":47},"Site 1001","Banja Luka","78000","Bosnia and Herzegovina","BA",{"type":81,"coordinates":220},[221,222],17.20629,44.77879,{"lat":222,"lon":221},{"facility":225,"status":137,"city":226,"state":47,"zip":227,"country":217,"countryCode":218,"cosmosGeoPoint":228,"geoPoint":232,"contacts":47},"Site 1002","Sarajevo","71000",{"type":81,"coordinates":229},[230,231],18.35644,43.84864,{"lat":231,"lon":230},{"facility":234,"status":137,"city":235,"state":47,"zip":236,"country":217,"countryCode":218,"cosmosGeoPoint":237,"geoPoint":241,"contacts":47},"Site 1003","Tuzla","75000",{"type":81,"coordinates":238},[239,240],18.66709,44.53842,{"lat":240,"lon":239},{"facility":243,"status":137,"city":244,"state":47,"zip":245,"country":246,"countryCode":247,"cosmosGeoPoint":248,"geoPoint":252,"contacts":47},"Site 1202","Panagyurishte","4500","Bulgaria","BG",{"type":81,"coordinates":249},[250,251],24.19021,42.49518,{"lat":251,"lon":250},{"facility":254,"status":137,"city":255,"state":47,"zip":256,"country":246,"countryCode":247,"cosmosGeoPoint":257,"geoPoint":261,"contacts":47},"Site 1201","Sofia","1632",{"type":81,"coordinates":258},[259,260],23.32415,42.69751,{"lat":260,"lon":259},{"facility":263,"status":137,"city":264,"state":47,"zip":265,"country":266,"countryCode":267,"cosmosGeoPoint":268,"geoPoint":272,"contacts":47},"Site 1401","Tbilisi","0112","Georgia","GE",{"type":81,"coordinates":269},[270,271],44.83412,41.69143,{"lat":271,"lon":270},{"facility":274,"status":137,"city":275,"state":47,"zip":276,"country":277,"countryCode":278,"cosmosGeoPoint":279,"geoPoint":283,"contacts":47},"Site 1902","Belgrade","11080","Serbia","RS",{"type":81,"coordinates":280},[281,282],20.46513,44.80401,{"lat":282,"lon":281},{"facility":285,"status":137,"city":286,"state":47,"zip":47,"country":287,"countryCode":47,"cosmosGeoPoint":288,"geoPoint":292,"contacts":47},"Site 2901","Busan","South Korea",{"type":81,"coordinates":289},[290,291],129.03004,35.10168,{"lat":291,"lon":290},{"facility":294,"status":137,"city":295,"state":47,"zip":296,"country":287,"countryCode":47,"cosmosGeoPoint":297,"geoPoint":301,"contacts":47},"Site 2903","Seoul","03080",{"type":81,"coordinates":298},[299,300],126.9784,37.566,{"lat":300,"lon":299},{"facility":303,"status":137,"city":295,"state":47,"zip":304,"country":287,"countryCode":47,"cosmosGeoPoint":305,"geoPoint":307,"contacts":47},"Site 2904","05505",{"type":81,"coordinates":306},[299,300],{"lat":300,"lon":299},{"type":309,"investigatorFullName":47,"investigatorTitle":47,"investigatorAffiliation":47,"oldNameTitle":47,"oldOrganization":47},"SPONSOR","100402145","phase-1-a-study-of-azenosertib-zn-c3-in-patients-with-ovarian-cancer-100402145",false,"NCT04516447","A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer","A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer","MUIR","INCLUSION CRITERIA:\n\nFor Part 1:\n\n* Histologically or cytologically confirmed FIGO Stage III\u002FIV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal carcinoma.\n* Subjects must have received 1 or 2 prior therapeutic regimens\u002Flines of therapy in the advanced or metastatic setting. At least one regimen must have contained cisplatin or carboplatin.\n* The disease must be platinum resistant (ie, the PFI must have been \\\u003C 6 months). Platinum refractory disease (ie, PD during first-line platinum-based therapy) is allowed.\n\nFor Part 2 Dose Escalation:\n\nPrior therapy:\n\n• Subjects must have received 6 cycles of platinum-based doublet chemotherapy in the 1L or 2L setting as their most recent therapy\n\nResponse to prior platinum therapy:\n\n1. In the 1L setting: Complete Response, Partial Response, or Stable Disease to platinum-based chemotherapy.\n2. In the 2L setting:\n\n   1. Progressive Disease \\>183 days after receiving the last dose of platinum chemotherapy in the 1L setting,\n   2. Complete Response, Partial Response, or Stable Disease to 2L platinum-based chemotherapy.\n\n      * Adequate hematologic, and organ function\n\nFor Part 2 Dose Expansion:\n\n* Subjects must have at least 4 cycles of platinum-based chemotherapy in 2L and have Complete Response, Partial Response, or Stable Disease\n* Subjects must have progressed while on a PARP inhibitor for 1L maintenance Additional protocol-defined inclusion criteria may apply\n\nEXCLUSION CRITERIA:\n\n* Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor.\n* Subjects with carcinosarcomas (even if there is a serous component)\n* A serious illness or medical condition(s)\n* Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.\n\nAdditional protocol-defined exclusion criteria may apply","FEMALE","18 Years",{"count":321,"type":322},172,"ESTIMATED","INTERVENTIONAL",[325],"PHASE1","This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.",[328,329,330,331],"Solid Tumor","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer",[328],"2026-04-01",{"date":335,"type":336},"2026-04-07","ACTUAL",{"date":338,"type":336},"2020-10-26",{"date":340,"type":322},"2028-06-30",{"name":5,"class":6},24]